JCR Pharmaceuticals Co., Ltd.
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1975-01-01
- Employees
- 934
- Market Cap
- -
- Website
- http://www.jcrpharm.co.jp
An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- JCR Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT06488924
- Locations
- 🇯🇵
Hiroshima University Hospital, Hiroshima, Japan
🇯🇵University of the Ryukyus Hospital, Okinawa, Japan
🇯🇵National Center for Child Health and Development, Tokyo, Japan
Phase I/II Study of JR-441 in Patients With Mucopolysaccharidosis Type IIIA
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- JCR Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06095388
- Locations
- 🇩🇪
Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- JCR Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT05594992
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇦🇷Hospital Universitario Austral, Buenos Aires, Argentina
🇮🇹Osp. Pediatrico Bambino Gesù, IRCCS, Rome, Italy
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
- Conditions
- Mucopolysaccharidosis II
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- JCR Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT04573023
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇺🇸Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)
- First Posted Date
- 2020-07-01
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- JCR Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT04453085
- Locations
- 🇯🇵
National Hospital Organization Kokura Medical Center, Kitakyushu, Japan
🇯🇵Osaka Metropolitan University Hospital, Osaka, Japan
🇺🇸UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- JCR Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 27
- Registration Number
- NCT04348136
- Locations
- 🇯🇵
Fukui Clinical site, Fukui, Japan
🇯🇵Fukuoka Clinical site 2, Fukuoka, Japan
🇯🇵Fukuoka Clinical site, Fukuoka, Japan
A Study of JR-171 in Patients With Mucopolysaccharidosis I
- Conditions
- Mucopolysaccharidosis I
- Interventions
- Drug: JR-171 (lepunafusp alfa)
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- JCR Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT04227600
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
🇺🇸UCSF Benioff Children's Hospital Oakland, Oakland, California, United States
🇯🇵Fukuoka Children's Hospital, Fukuoka, Japan
An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2023-06-23
- Lead Sponsor
- JCR Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT03708965
- Locations
- 🇧🇷
Grupo de Pesquisa Clínica em Genética Médica - HCPA, Porto Alegre, Brazil
🇧🇷Igeim - Unifesp, São Paulo, Brazil
A Study of JR-141 in Patients With Mucopolysaccharidosis II
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- JCR Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT03568175
- Locations
- 🇯🇵
Osaka Clinical site, Osaka, Japan
🇯🇵Saitama Clinical site, Saitama, Japan
🇯🇵Fukui Clinical site, Fukui, Japan
A Study of JR-141 in Patients With Mucopolysaccharidosis II
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- JCR Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 18
- Registration Number
- NCT03359213
- Locations
- 🇧🇷
Igeim - Unifesp, São Paulo, Brazil
🇧🇷Grupo de Pesquisa Clínica em Genética Médica - HCPA, Porto Alegre, Brazil